News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Y's Therapeutics, Inc. Initiates Phase II Trial With YSPSL in Liver Transplant Patients for Prevention of Ischemic Reperfusion (I/R) Injury


5/2/2007 10:38:01 AM

TOKYO and BURLINGAME, CA -- (MARKET WIRE) -- May 02, 2007 -- Y's Therapeutics, a privately held biopharmaceutical company, announced the initiation of a Phase II clinical trial of its lead compound, YSPSL, for prevention of ischemic reperfusion injury (I/R) in liver transplant patients. The clinical trial is a randomized, double-blind, placebo-controlled study designed to enroll 12 patients undergoing cadaveric orthotopic liver transplantation at Dumont UCLA Transplant Center, a leading US liver transplant center.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES